11 HURLEY ST., CAMBRIDGE, MA
Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Announces Second Quarter 2026 Results and Business Updates
Stockholders Elect Bernadette Connaughton and Elliott Levy as Directors
Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Other Events
Announces Pricing of Up to $319.4 Million Public Offering
Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Announces First Quarter 2026 Results and Business Updates
Q1
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement
Confidential Treatment Order
SEC Staff Correspondence